It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

To gain competitive advantage from gen AI, enterprises need to be able to add their own expertise to off-the-shelf systems. Yet standard enterprise data stores aren't a good fit to train large ...

As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in ...

Get the Real Story Behind Every Major Earnings Report RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

Persistent Systems announced the launch of Pi-OmniKG, an advanced AI-driven knowledge graph solution developed with Google Cloud technology ... Pi-OmniKG is built using Google Cloud's advanced ...

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...